Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
about
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dogAmerican Heart Association atrial fibrillation research summit: a conference report from the American Heart AssociationSynergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atriaEffect of dronedarone on Na+, Ca2+ and HCN channels.Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Advances in the Pharmacological Treatment of Atrial Fibrillation.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent blockMechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical modelNovel pharmacological targets for the rhythm control management of atrial fibrillation.Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolAtrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.Role of late sodium channel current block in the management of atrial fibrillation.Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparationsAtrial-selective sodium channel block for the treatment of atrial fibrillation.Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.New developments in atrial antiarrhythmic drug therapy.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.Vernakalant for the conversion of atrial fibrillation: the new kid on the block?Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.Advances in the Pharmacologic Management of Atrial Fibrillation.Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy.Electrocardiographic P wave changes after thoracoscopic pulmonary vein isolation for atrial fibrillation.Larger late sodium current density as well as greater sensitivities to ATX II and ranolazine in rabbit left atrial than left ventricular myocytes.Atrial selective effect of amiodarone to increase threshold of excitation.Atrial selectivity in Na+channel blockade by acute amiodarone.
P2860
Q24607775-AA9B8AD5-EC35-48B6-9DCC-D29A4CE5E577Q30425918-44A2F4CD-060A-4116-8C5E-DADBB771E36CQ33665436-BC224030-2618-43EA-B886-61E840C575FBQ33807062-590C3A3F-CF23-4662-8C5E-8E23929A325BQ33916951-EF6C8A13-6656-4BBA-BFA9-E123A27224E1Q34181734-2AE8A57A-99E1-4DC7-97CB-5E745A5F7174Q34383573-C4D4F350-104D-47CC-B901-BB459FB4FCB1Q35091243-CE2B9C4B-25BF-4D21-9F8B-5B8868845292Q35395995-1270A2B8-4EE5-4017-BCB0-AAE5BEDB0C7DQ35396014-DB005390-2CC5-4C66-A892-7A2F4913D184Q35489060-CD812800-E008-4672-9C82-36EDAC385FE3Q35650683-CA546A99-FEB9-4198-A077-B9911C43B850Q35897567-8C6D3B38-C58F-4643-B7FE-A3828661B07FQ36013079-4C998413-73DD-4C28-B06E-D83EC03CA6A6Q36534150-4143FDC3-662D-4722-87F4-B343D1533342Q36570112-A24E0323-0627-49F4-AA9B-4A463474C2E3Q37315220-9F8FE55F-0310-44BD-B105-450FD43B6304Q37494653-24722CB8-FEA2-4BBB-8BDD-1BC040903F1BQ37584282-DD4708BF-F274-4C28-A85B-3CB94901C32CQ37697498-9FB30D6A-4592-4059-9774-638556B9A655Q37844891-B3C498F7-7520-4B9B-8CD4-E809C06C665EQ38103541-D000CE6E-BFBF-47E1-A9F0-A2E06F63FFC6Q38205011-2BD0245B-B267-4B6A-A3CE-878F2B6D41B9Q38226807-2D89B917-55D8-4ECE-8FFC-4304B3A70564Q39760319-C6494CD1-28D5-4530-B997-2ABB43160031Q40426127-5C35655A-CA08-4E4B-B010-E954AF3B3A4FQ42432616-838C9497-19E3-475E-890D-D9272810D438Q42777572-666C292A-AC8F-47D6-8714-30227F9D6E3DQ42909841-7FC5F2B4-C4C9-4F8D-8257-B0F52E5C84D5Q44165966-F3164267-D129-4E03-AC5B-05EEB6DEF1C5Q44447235-4E38CADD-74FD-4DC7-9284-16C44527F032Q44676717-F657A97F-2D4E-430D-ACC7-79F4DE7AAD8CQ46219056-2AB54052-4E1F-4E3E-8B3A-DCA85C0FFBDF
P2860
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@en
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@nl
type
label
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@en
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@nl
prefLabel
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@en
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
@nl
P2093
P2860
P1433
P1476
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation
@en
P2093
Alexander Burashnikov
José M Di Diego
Leif Carlsson
Marcela Ferreiro
Serge Sicouri
P2860
P304
P356
10.1016/J.HRTHM.2008.09.015
P577
2008-09-16T00:00:00Z